13 November 2026
This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation 596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of this announcement via a regulatory information service, this information is considered to be in the public domain.
BEXIMCO PHARMACEUTICALS PLC.
Financial Results for the First Quarter Ended 30 September 2026
Beximco Pharmaceuticals PLC. ("Beximco Pharma" or "the Company"; AIM Symbol: BXP, LEI No.:213800IMBBD6TIOQGB56), the fast-growing manufacturer of generic pharmaceutical products and active pharmaceutical ingredients, today announces its unaudited results for the three-month period ended 30 September 2026. The financial statements have been released to the Dhaka and Chittagong Stock Exchanges in compliance with the requirements from the Bangladesh SEC.
Beximco Pharma Managing Director, S. M. Rabbur Reza, commented:
“We are pleased to share today’s results which demonstrate the underlying strength and resilience of Beximco Pharma’s business. Despite the ongoing macro-economic challenges, we have continued to deliver revenue and profitability growth into the new financial year, and we look forward to building on this progress for shareholders and patients as we continue to execute on our strategy and provide high-quality and affordable medicines to patients in Bangladesh and around the world.”
The detailed accounts can be viewed at the Company website: www.beximcopharma.com
For further information please visit www.beximcopharma.com or enquire to:
Beximco Pharma
S. M. Rabbur Reza, Managing Director
Tel: +880 2 58611001, Ext. 20111
Mohammad Ali Nawaz, Chief Financial Officer
Tel: +880 2 58611001, Ext. 20030
Mohammad Asad Ullah, FCS
Executive Director & Company Secretary
Tel: +880 2 41060531, Ext. 10140
SPARK Advisory Partners Limited (Nominated Adviser)
Mark Brady / Andrew Emmott
Tel: +44 (0)20 3368 3551 / 3555
SP Angel Corporate Finance LLP (Broker)
Matthew Johnson
Tel: +44 (0) 20 3470 0470
FTI Consulting
Ben Atwell / Sam Purewal / Lucy Molloy
Tel: +44 (0)20 3727 1000
Notes to Editors
About Beximco Pharmaceuticals PLC.
Beximco Pharma is a leading manufacturer and exporter of medicines based in Bangladesh. Since its inception in 1976, the Company remains committed to health and wellbeing of people across all the continents by providing access to contemporary medicines. Company’s broad portfolio of generics encompasses diverse delivery systems such as tablets, capsules, liquids, semi-solids, intravenous fluids, metered dose inhalers, dry powder inhalers, sterile ophthalmic drops, insulins, prefilled syringes, injectables, nebuliser solutions, oral soluble films etc. The Company also undertakes contract manufacturing for multinational and leading global generic pharmaceutical companies.
Beximco Pharma’s state-of-the-art manufacturing facilities are certified by global regulatory authorities of USA, Europe, Australia, Canada, GCC and Latin America, among others and it has a geographic footprint in more than 50 countries. More than 6,000 employees are driving the company towards achieving its aspiration to be among the most admired companies in the region.
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of financial position (Un-audited)
As at 30 September 2026
|
|
30 September 2026 |
|
Taka ‘000
30 June 2026 |
|
ASSETS |
|
|
|
|
|
|
|
|
|
Property, plant and equipment |
45,768,049 |
|
45,602,684 |
|
Right-of-use assets |
344,443 |
|
359,773 |
|
Intangible assets |
4,462,167 |
|
4,551,852 |
|
Deferred tax asset |
16,695 |
|
19,651 |
|
Goodwill |
674,570 |
|
674,570 |
|
Investment in associates |
15,365 |
|
15,365 |
|
Other investments |
5,430 |
|
6,733 |
|
Total non-current assets |
51,286,719 |
|
51,230,628 |
|
|
|
|
|
|
Inventories |
14,586,089 |
|
13,988,599 |
|
Spares and supplies |
969,145 |
|
1,010,233 |
|
Trade and other receivables |
3,189,015 |
|
3,669,562 |
|
Loans, advances, deposits and prepayments |
3,108,316 |
|
3,220,130 |
|
Advance income tax |
415,097 |
|
402,402 |
|
Short term investment |
1,500,000 |
|
950,000 |
|
Cash and cash equivalents |
8,466,259 |
|
6,668,012 |
|
Total current assets |
32,233,921 |
|
29,908,938 |
|
TOTAL ASSETS |
83,520,640 |
|
81,139,566 |
|
|
|
|
|
|
EQUITY AND LIABILITIES |
|
|
|
|
Share capital |
4,461,121 |
|
4,461,121 |
|
Share premium |
5,269,475 |
|
5,269,475 |
|
Excess of issue price over face value of GDRs |
1,689,637 |
|
1,689,637 |
|
Capital reserve on merger |
294,951 |
|
294,951 |
|
Revaluation surplus |
1,130,144 |
|
1,130,821 |
|
Unrealized gain/(loss) |
2,604 |
|
3,908 |
|
Retained earnings |
51,795,427 |
|
49,241,292 |
|
Total shareholders' equity |
64,643,359 |
|
62,091,205 |
|
Non-controlling interest |
4,146,833 |
|
4,103,149 |
|
|
|
|
|
|
TOTAL EQUITY |
68,790,192 |
|
66,194,354 |
|
|
|
|
|
|
Long term borrowings-net of current maturity |
1,462,374 |
|
1,738,988 |
|
Liability for gratuity and WPPF |
3,788,877 |
|
3,395,314 |
|
Deferred tax liability |
2,796,303 |
|
2,758,010 |
|
Non-current liabilities |
8,047,554 |
|
7,892,312 |
|
|
|
|
|
|
Short term borrowings |
1,909,140 |
|
2,303,467 |
|
Long term borrowings-current maturity |
574,942 |
|
586,629 |
|
Trade and other payables |
1,865,496 |
|
1,952,971 |
|
Accrued expenses |
1,189,545 |
|
1,422,556 |
|
Dividend payable |
122,629 |
|
137,954 |
|
Income tax payable |
1,021,142 |
|
649,323 |
|
Total current liabilities |
6,682,894 |
|
7,052,900 |
|
Total liabilities |
14,730,448 |
|
14,945,212 |
|
TOTAL EQUITY AND LIABILITIES |
83,520,640 |
|
81,139,566 |
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of profit or loss and other comprehensive income (Un-audited)
For the period July 2026-September 2026
|
|
|
|
|
Taka ‘000
|
|
|
|
|
|
|
|
|
|
July 2026–September 2026 |
|
July 2025–September 2025 |
|
|
|
|
|
|
|
Net revenue |
|
14,657,933 |
|
13,794,829 |
|
Cost of goods sold |
|
(7,482,950) |
|
(7,132,749) |
|
Gross profit |
|
7,174,983 |
|
6,662,080 |
|
|
|
|
|
|
|
General and administrative expenses |
|
(384,332) |
|
(354,695) |
|
Selling, marketing and distribution expenses |
|
(3,392,187) |
|
(3,013,639) |
|
Operating expenses |
|
(3,776,519) |
|
(3,368,334) |
|
Profit from operations |
|
3,398,464 |
|
3,293,746 |
|
|
|
|
|
|
|
Other income |
|
304,844 |
|
169,395 |
|
Finance cost |
|
(105,885) |
|
(186,310) |
|
Profit before tax and WPPF |
|
3,597,423 |
|
3,276,831 |
|
Contribution to WPPF |
|
(172,466) |
|
(157,156) |
|
|
|
|
|
|
|
Profit before tax |
|
3,424,957 |
|
3,119,675 |
|
Current tax |
|
(786,566) |
|
(702,569) |
|
Deferred tax |
|
(41,446) |
|
(15,845) |
|
Income tax expenses |
|
(828,012) |
|
(718,414) |
|
Profit after tax |
|
2,596,945 |
|
2,401,261 |
|
|
|
|
|
|
|
Owners of the Company |
|
2,553,261 |
|
2,363,099 |
|
Non-controlling interest |
|
43,684 |
|
38,162 |
|
Profit/(loss) attributable |
|
2,596,945 |
|
2,401,261 |
|
Other comprehensive income/(loss) |
|
(1,304) |
|
- |
|
Total comprehensive income |
|
2,595,641 |
|
2,401,261 |
|
|
|
|
|
|
|
Owners of the Company |
|
2,551,957 |
|
2,363,099 |
|
Non-controlling interest |
|
43,684 |
|
38,162 |
|
Total comprehensive income attributable |
|
2,595,641 |
|
2,401,261 |
|
|
|
|
|
|
|
Earnings per share (EPS) |
|
5.72 |
|
5.30 |
|
|
|
|
|
|
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of changes in equity (Un-audited)
For the period July 2026-September 2026
|
For the period July 2026-September 2026 |
Taka ‘000
|
|||||||||
|
|
Share capital |
Share premium |
Excess of issue price over face value of GDRs |
Capital reserve on merger |
Revaluation surplus |
Unrealized gain/(loss) |
Retained earnings |
Equity attributable to owners of the Company |
Non-controlling interest |
Total |
|
Balance as on 01 July 2026 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,130,821 |
3,908 |
49,241,292 |
62,091,205 |
4,103,149 |
66,194,354 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total comprehensive income: |
|
|||||||||
|
Profit for the period |
- |
- |
- |
- |
- |
- |
2,553,261 |
2,553,261 |
43,684 |
2,596,945 |
|
Other comprehensive income/(loss) |
- |
- |
- |
- |
- |
(1,304) |
- |
(1,304) |
- |
(1,304) |
|
Transactions with the shareholders: |
|
|||||||||
|
Cash dividend |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Others: |
|
|||||||||
|
Adjustment for depreciation on revalued assets |
- |
- |
- |
- |
(874) |
- |
874 |
- |
- |
- |
|
Adjustment for deferred tax on revalued assets |
- |
- |
- |
- |
197 |
- |
- |
197 |
- |
197 |
|
Balance as on 30 September 2026 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,130,144 |
2,604 |
51,795,427 |
64,643,359 |
4,146,833 |
68,790,192 |
|
Net assets value (NAV) per share Tk. 144.90 |
||||||||||
|
For the period July 2025-September 2025 |
||||||||||
|
|
Share capital |
Share premium |
Excess of issue price over face value of GDRs |
Capital reserve on merger |
Revaluation surplus |
Unrealized gain/(loss) |
Retained earnings |
Equity attributable to owners of the Company |
Non-controlling interest |
Total |
|
Balance as on 01 July 2025 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,133,870 |
18,149 |
40,239,934 |
53,107,137 |
3,977,499 |
57,084,636 |
|
Total comprehensive income: |
|
|
|
|
|
|
|
|
|
|
|
Profit for the period |
- |
- |
- |
- |
- |
- |
2,363,099 |
2,363,099 |
38,162 |
2,401,261 |
|
Other comprehensive income/(loss) |
- |
- |
- |
- |
- |
- |
- |
- |
- |
- |
|
Transactions with the shareholders: |
||||||||||
|
Cash dividend |
- |
|
|
|
|
|
- |
- |
- |
- |
|
Others: |
||||||||||
|
Adjustment for depreciation on revalued assets |
- |
- |
- |
- |
(984) |
- |
984 |
- |
- |
- |
|
Adjustment for deferred tax on revalued assets |
- |
- |
- |
- |
221 |
- |
- |
221 |
- |
221 |
|
Balance as on 30 September 2025 |
4,461,121 |
5,269,475 |
1,689,637 |
294,951 |
1,133,107 |
18,149 |
42,604,017 |
55,470,457 |
4,015,661 |
59,486,118 |
|
Net assets value (NAV) per share Tk. 124.34 |
||||||||||
Beximco Pharmaceuticals PLC. and its Subsidiaries
Consolidated statement of cash flows (Un-audited)
For the period July 2026-September 2026
|
|
July 2026– September 2026 |
|
Taka ‘000
July 2025– September 2025 |
|
Cash flows from operating activities: |
|
|
|
|
|
|
|
|
|
Cash receipts from customers and others |
15,258,385 |
|
13,822,950 |
|
Cash paid to suppliers and employees |
(11,276,123) |
|
(10,498,856) |
|
Cash generated from operations |
3,982,262 |
|
3,324,094 |
|
|
|
|
|
|
Interest paid |
(118,697) |
|
(199,501) |
|
Interest received |
157,544 |
|
63,704 |
|
Income tax paid |
(427,442) |
|
(450,451) |
|
Net cash generated from operating activities |
3,593,667 |
|
2,737,846 |
|
|
|
|
|
|
Cash flows from investing activities: |
|
|
|
|
Acquisition of property, plant and equipment |
(576,511) |
|
(984,442) |
|
Intangible assets |
(3,561) |
|
(92,909) |
|
Disposal of property, plant and equipment |
14,018 |
|
- |
|
Short term investment |
(550,000) |
|
(100,000) |
|
Net cash used in investing activities |
(1,116,054) |
|
(1,177,351) |
|
|
|
|
|
|
Cash flows from financing activities: |
|
|
|
|
|
|
|
|
|
Net increase/(decrease) in long term borrowings |
(271,399) |
|
(463,728) |
|
Net increase/(decrease) in short term borrowings |
(394,327) |
|
7,978 |
|
Dividend paid |
(15,325) |
|
(163,858) |
|
Net cash from/(used in) financing activities |
(681,051) |
|
(619,608) |
|
Increase/(decrease) in cash and cash equivalents |
1,796,562 |
|
940,887 |
|
Opening cash and cash equivalents |
6,668,012 |
|
1,700,097 |
|
Effect of exchange rate changes on cash and cash equivalents |
1,685 |
|
8,136 |
|
Closing cash and cash equivalents |
8,466,259 |
|
2,649,120 |
|
|
|
|
|
|
Net operating cash flows per share |
8.06 |
|
6.14 |
|
|
|
|
|